Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
osts associated with defending or prosecutinglitigation matters and a... Contact: Mona J. Walsh (Investors) ... Edelman ... 212-704-4598 ... mona.walsh@edelma...
osts associated with defending or prosecuting
litigation matters and any material adverse result from such matters; the
possibility that PharmaStem could seek to appeal the Court of Appeals
decision or that a second case by PharmaStem based on two other patents
closely related to the '553 and '681 patents, which has been stayed pending
this appeal and reexamination of the patents in the U.S. Patent and
Trademark Office, could continue; decreases in asset valuations; any
continued negative effect from adverse publicity in the past year regarding
the Company's business operations; any negative consequences resulting from
deriving, shipping and storing specimens at a second location; and other
risks and uncertainties. The foregoing list is not exhaustive, and the
Company disclaims any obligations to subsequently revise any
forward-looking statements to reflect events or circumstances after the
date of such statements. Readers should carefully review the risk factors
described in other documents the Company files from time to time with the
Securities and Exchange Commission, including the most recent Annual Report
on Form 10-KSB, Quarterly Reports on Form 10-Q and any Current Reports on
Form 8-K filed by the Company.